7.79
price down icon2.87%   -0.23
after-market アフターアワーズ: 7.75 -0.04 -0.51%
loading
前日終値:
$8.02
開ける:
$7.96
24時間の取引高:
4.40M
Relative Volume:
1.04
時価総額:
$1.99B
収益:
$885.72M
当期純損益:
$-457.98M
株価収益率:
-4.385
EPS:
-1.7765
ネットキャッシュフロー:
$293.05M
1週間 パフォーマンス:
-8.89%
1か月 パフォーマンス:
-7.59%
6か月 パフォーマンス:
-18.17%
1年 パフォーマンス:
+15.92%
1日の値動き範囲:
Value
$7.74
$8.015
1週間の範囲:
Value
$7.74
$8.55
52週間の値動き範囲:
Value
$6.23
$11.22

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Name
名前
Biocryst Pharmaceuticals Inc
Name
セクター
Healthcare (1052)
Name
電話
919-859-1302
Name
住所
4505 EMPEROR BOULEVARD, DURHAM, NC
Name
職員
435
Name
Twitter
@biocrystpharma
Name
次回の収益日
2026-11-02
Name
最新のSEC提出書
Name
BCRX's Discussions on Twitter

Compare BCRX vs TAK, TEVA, HLN, ZTS, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
BCRX icon
BCRX
Biocryst Pharmaceuticals Inc
7.79 1.99B 885.72M -457.98M 293.05M -1.7765
TAK icon
TAK
Takeda Pharmaceutical Co Adr
19.67 62.84B 29.91B 1.30B 3.49B 0.4056
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
41.50 48.40B 17.53B 1.58B 444.18M 1.3457
HLN icon
HLN
Haleon Plc Adr
10.13 44.55B 14.54B 2.22B 2.58B 0.4871
ZTS icon
ZTS
Zoetis Inc
79.38 32.80B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
533.12 22.87B 3.17B 1.29B 1.01B 27.09

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-09-10 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2026-07-13 再開されました JP Morgan Neutral
2026-02-18 再開されました Evercore ISI Outperform
2025-10-15 再開されました TD Cowen Buy
2025-10-01 ダウングレード Evercore ISI Outperform → In-line
2025-04-29 開始されました Cantor Fitzgerald Overweight
2025-02-25 開始されました Wedbush Outperform
2023-11-20 再開されました JP Morgan Overweight
2023-09-18 アップグレード RBC Capital Mkts Sector Perform → Outperform
2023-08-04 アップグレード Jefferies Hold → Buy
2023-07-13 アップグレード BofA Securities Neutral → Buy
2023-02-22 アップグレード Needham Hold → Buy
2022-11-02 アップグレード Evercore ISI In-line → Outperform
2022-08-05 ダウングレード Evercore ISI Outperform → In-line
2022-08-05 ダウングレード Oppenheimer Outperform → Perform
2022-04-18 ダウングレード Barclays Overweight → Equal Weight
2022-04-11 ダウングレード BofA Securities Buy → Neutral
2021-12-10 開始されました Oppenheimer Outperform
2021-08-06 ダウングレード Jefferies Buy → Hold
2021-08-03 開始されました Cantor Fitzgerald Overweight
2021-03-01 開始されました Cowen Outperform
2020-09-29 再開されました JP Morgan Overweight
2020-06-17 開始されました BTIG Research Neutral
2020-05-05 アップグレード Barclays Equal Weight → Overweight
2019-11-15 アップグレード BofA/Merrill Neutral → Buy
2019-05-24 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2018-11-16 再開されました Piper Jaffray Overweight
2018-08-08 再開されました JP Morgan Overweight
2018-07-17 アップグレード BofA/Merrill Underperform → Neutral
2018-06-22 開始されました Seaport Global Securities Neutral
2018-01-02 アップグレード RBC Capital Mkts Sector Perform → Outperform
2017-12-20 開始されました Barclays Equal Weight
2017-09-15 開始されました RBC Capital Mkts Sector Perform
2017-09-06 アップグレード JP Morgan Neutral → Overweight
2017-09-06 アップグレード Jefferies Hold → Buy
2017-02-16 開始されました Ladenburg Thalmann Buy
2016-08-12 アップグレード Piper Jaffray Neutral → Overweight
2016-08-04 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 繰り返されました FBR Capital Outperform
2016-02-09 ダウングレード JP Morgan Overweight → Neutral
2016-02-09 ダウングレード Needham Buy → Hold
すべてを表示

Biocryst Pharmaceuticals Inc (BCRX) 最新ニュース

pulisher
Oct 13, 2026

BioCryst Pharmaceuticals, Inc. (BCRX) Options ChainYahoo Finance - Yahoo! Finance Canada

Oct 13, 2026
pulisher
Oct 10, 2026

BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $15 - Moomoo

Oct 10, 2026
pulisher
Oct 09, 2026

People on the Move: BioCryst Forms Scientific Advisory Board of Seven Rare Disease Leaders - BioBuzz

Oct 09, 2026
pulisher
Oct 07, 2026

BioCryst Pharmaceuticals stock fell 1.85 percent on October 6 - AD HOC NEWS

Oct 07, 2026
pulisher
Oct 07, 2026

BioCryst Pharmaceuticals stock gets USD 20.50 target as BioCryst forms board - AD HOC NEWS

Oct 07, 2026
pulisher
Oct 07, 2026

BioCryst Pharmaceuticals stock gets USD 20.50 target as BioCryst forms board - AD HOC NEWS

Oct 07, 2026
pulisher
Oct 06, 2026

BioCryst Pharmaceuticals Inc (BO1.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada

Oct 06, 2026
pulisher
Oct 05, 2026

BioCryst Pharmaceuticals stock gets a new science board - AD HOC NEWS

Oct 05, 2026
pulisher
Oct 05, 2026

Discipline and Rules-Based Execution in BCRX Response - Stock Traders Daily

Oct 05, 2026
pulisher
Oct 05, 2026

Biocryst Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board - www.marketscreener.com

Oct 05, 2026
pulisher
Oct 05, 2026

BioCryst forms scientific advisory board for R&D strategy By Investing.com - Investing.com India

Oct 05, 2026
pulisher
Oct 05, 2026

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth - GlobeNewswire

Oct 05, 2026
pulisher
Oct 05, 2026

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth - GlobeNewswire

Oct 05, 2026
pulisher
Oct 05, 2026

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth - GlobeNewswire

Oct 05, 2026
pulisher
Oct 04, 2026

JPMorgan raises target for BioCryst Pharmaceuticals stock - AD HOC NEWS

Oct 04, 2026
pulisher
Sep 30, 2026

BioCryst Pharmaceuticals Price Target Raised to $13.00/Share From $12.00 by JP Morgan - Moomoo

Sep 30, 2026
pulisher
Sep 30, 2026

BCRX Maintained by JP Morgan -- Price Target Raised to $13.00 - GuruFocus

Sep 30, 2026
pulisher
Sep 30, 2026

J.P. Morgan Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Raises Target Price to $13 - Moomoo

Sep 30, 2026
pulisher
Sep 29, 2026

Claude AI Just Bought These 2 Pharma Stocks - finance.yahoo.com

Sep 29, 2026
pulisher
Sep 25, 2026

(BCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Sep 25, 2026
pulisher
Sep 23, 2026

BioCryst Pharmaceuticals, Inc. (BCRX) Options ChainYahoo Finance - Yahoo! Finance Canada

Sep 23, 2026
pulisher
Sep 23, 2026

Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks? - finance.yahoo.com

Sep 23, 2026
pulisher
Sep 22, 2026

BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation - Stocktwits

Sep 22, 2026
pulisher
Sep 22, 2026

BioCryst Pharmaceuticals stock gains 0.92 percent as earnings beat estimates - AD HOC NEWS

Sep 22, 2026
pulisher
Sep 21, 2026

Biopharma Stock With Layers of Technical Support in Place - Yahoo Finance

Sep 21, 2026
pulisher
Sep 21, 2026

Biopharma Stock With Layers of Technical Support in Place - Schaeffer's Investment Research

Sep 21, 2026
pulisher
Sep 18, 2026

BioCryst Eyes $1B Rare-Disease Future Through External Innovation - Yahoo Finance

Sep 18, 2026
pulisher
Sep 17, 2026

BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs - AlphaStreet

Sep 17, 2026
pulisher
Sep 17, 2026

BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs - Yahoo Finance

Sep 17, 2026
pulisher
Sep 14, 2026

BioCryst Pharmaceuticals (BCRX) Could Be 62% Undervalued On Its ORLADEYO Growth Story - Yahoo Finance

Sep 14, 2026
pulisher
Sep 11, 2026

BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity (NASDAQ:BCRX) - Seeking Alpha

Sep 11, 2026
pulisher
Sep 10, 2026

BCRX Downgraded by RBC Capital -- Price Target Lowered to $11.00 - GuruFocus

Sep 10, 2026
pulisher
Sep 09, 2026

RBC Downgrades BioCryst to Sector Perform Amid Competitive Pressures - Intellectia AI

Sep 09, 2026
pulisher
Sep 09, 2026

BCRX Looks 24.9% Undervalued on GF Value™ Despite Unprofitabilit - GuruFocus

Sep 09, 2026
pulisher
Sep 09, 2026

BioCryst Pharma (BCRX): ORLADEYO Growth And Pipeline Catalysts Shape The Long-Term Outlook - RTTNews

Sep 09, 2026
pulisher
Sep 08, 2026

BioCryst's Orladeyo Approved for HAE Attack Prevention - Intellectia AI

Sep 08, 2026
pulisher
Sep 08, 2026

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease - Yahoo Finance

Sep 08, 2026
pulisher
Sep 08, 2026

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease - Stocktwits

Sep 08, 2026
pulisher
Sep 08, 2026

CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio - manilatimes.net

Sep 08, 2026
pulisher
Sep 08, 2026

CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio - Yahoo Finance

Sep 08, 2026
pulisher
Sep 08, 2026

BCRX Reiterated by Needham -- Price Target Maintained at $16 - GuruFocus

Sep 08, 2026
pulisher
Sep 08, 2026

TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook - Investing.com Canada

Sep 08, 2026
pulisher
Sep 08, 2026

TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook - Investing.com India

Sep 08, 2026
pulisher
Sep 04, 2026

(BCRX) Volatility Zones as Tactical Triggers - Stock Traders Daily

Sep 04, 2026
pulisher
Sep 03, 2026

C5 inhibitors disclosed in Biocryst patents - BioWorld News

Sep 03, 2026
pulisher
Sep 01, 2026

BioCryst to Present at Upcoming Investor Conference - marketscreener.com

Sep 01, 2026
pulisher
Sep 01, 2026

BioCryst to Present at Upcoming Investor Conference - GlobeNewswire

Sep 01, 2026
pulisher
Sep 01, 2026

BioCryst to Present at Upcoming Investor Conference - Yahoo Finance

Sep 01, 2026
pulisher
Sep 01, 2026

Morgan Stanley's healthcare conference is set to feature BioCryst on Sept. 15. - Stock Titan

Sep 01, 2026
pulisher
Aug 31, 2026

BioCryst stock holds firm after a Q2 revenue beat - ad-hoc-news.de

Aug 31, 2026

Biocryst Pharmaceuticals Inc (BCRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Biocryst Pharmaceuticals Inc (BCRX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Amy McKee
Director
May 18 '26
Proposed Sale
8.94
11,180
99,906
0
Barnes Alane P
Chief Legal Officer
May 13 '26
Sale
9.54
62,500
596,250
400,703
Barnes Alane P
Chief Legal Officer
May 13 '26
Option Exercise
5.04
62,500
315,000
463,203
Barnes Alane P
Officer
May 13 '26
Proposed Sale
9.54
62,500
596,250
0
HEGGIE THERESA
Director
Mar 20 '26
Proposed Sale
10.11
49,933
504,620
0
HEGGIE THERESA
Director
Mar 20 '26
Option Exercise
6.30
49,933
314,578
115,285
HEGGIE THERESA
Director
Mar 20 '26
Sale
10.11
49,933
504,823
65,352
Barnes Alane P
Chief Legal Officer
Mar 16 '26
Option Exercise
5.51
150,000
826,500
550,703
Barnes Alane P
Chief Legal Officer
Mar 16 '26
Sale
9.15
150,000
1,372,500
400,703
Barnes Alane P
Officer
Mar 16 '26
Proposed Sale
9.15
150,000
1,372,007
0
$10.01
price down icon 2.82%
$10.31
price up icon 2.38%
$5.00
price down icon 5.84%
$37.88
price down icon 4.27%
$16.63
price up icon 0.91%
$72.29
price up icon 0.01%
大文字化:     |  ボリューム (24 時間):